Skip to main content

Myriad Genetics riskScore

Myriad Genetics has launched riskScore, which employs a proprietary algorithm combining analysis of 80 SNPs and patients' personal and family history of cancer to determine a woman's risk of breast cancer. Results from this test will be reported alongside Myriad's myRisk Hereditary Cancer test, a 28-gene panel that gauges patients' risk for for eight cancers. RiskScore will help guide decisions for asymptomatic patients who get negative myRisk results, providing definitive answers to the 90 percent of patients testing negative for hereditary cancer genes, the company noted. Myriad has completed two validation studies in patients of European descent that it will present at upcoming conferences.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.